Corcept Q1 revenue rises but misses analyst estimates

Overview

• U.S. drugmaker's Q1 revenue rose yr/yr but missed analyst expectations

• Company posted Q1 net loss as operating expenses increased for Lifyorli launch and growth initiatives

• FDA approved Lifyorli in March 2026 for platinum-resistant ovarian cancer

Outlook

• Corcept raises 2026 revenue guidance to $950–$1,050 mln

• Company expects to return to profitability in second qtr 2026

• Corcept anticipates EMA approval of Lifyorli for ovarian cancer by end of 2026

Result Drivers

• HIGHER OPERATING EXPENSES - Co said increased spending for Lifyorli launch and Cushing’s syndrome growth initiatives drove up operating expenses

• PRODUCT LAUNCH PREPARATION - Q1 was last quarter with only one marketed product, as Lifyorli was approved in March and began contributing in April

• CUSHING’S SYNDROME DEMAND - Co reported successful transition to new pharmacy vendor and record patient starts for Korlym and authorized generic in March and April

Company press release: ID:nBw7Xf8Yxa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Corcept Therapeutics Inc is $60.00, about 28.8% above its April 29 closing price of $46.59

• The stock recently traded at 61 times the next 12-month earnings vs. a P/E of 71 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.